GVR Report cover Spine Biologics Market Size, Share & Trends Report

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Bone Graft Substitutes, Spinal Allografts, Cell-based Matrix), By End Use (Hospitals, ASCs), And Segment Forecasts, 2019 - 2026

  • Report ID: GVR-3-68038-588-5
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2017
  • Industry: Healthcare

Industry Insights

The global spine biologics market size was estimated at USD 1.8 billion in 2018 and is anticipated to expand at a CAGR of 4.2% over the forecast period. Increasing prevalence of degenerative spine disorders and a subsequent increase in treatment rates, advancements in bone grafting procedures, and high demand for minimally invasive procedures are some of the key contributing factors for market growth.

Spine biologics consists of biomaterials that can be used in the treatment of degenerative disc diseases, spinal cord injuries, and bone fusion surgeries. The usage of these products has always been crucial in spine surgery. Spinal fusion is a procedure used to correct defects in small bones (vertebrae) in the spine.

U.S. spine biologics Market

Surgeons are using advanced biological mechanisms for the treatment of spine deformities, such as extreme lateral interbody fusion and direct lateral interbody fusion. According to a research article published in BMC Musculoskeletal Disorders in 2018, the study concluded that the minimally invasive approach to lateral interbody fusion technology has the benefit of less injury and swift recovery post-surgery. This is an effective and safe treatment for spine disorders such as thoracic and lumbar spinal tuberculosis. Advancements in biomaterials make it easy for surgeons to treat people suffering from spine-related disorders such as disc degeneration and scoliosis.

Industry players have been focusing on the development of technologically advanced and cost-effective products to gain a competitive advantage. For instance, in 2018, NuVasive expanded its biologics business line with the launch of AttraX Scaffold. Collaborations, acquisitions, and mergers are also part of companies’ growth strategies. In May 2016, Stryker procured Orthovita Inc., a maker of biologics used in spine surgery, for USD 316 million to strengthen its spine biologics and implants capabilities.

Product Insights

Based on the product, the global market for spine biologics has been classified into spinal allografts, bone graft substitutes, and cell-based matrix. Spinal allografts dominated the overall market in 2018 owing to the numerous benefits associated with its usage. Adoption of allografts over autografts is swiftly increasing owing to properties such as immediate structural support and osteoconductivity. Moreover, allografts do not require another surgery to harvest the bone, which results in reduced surgery time and wound healing. Natural bone grafts are harvested from a patient’s or a donor’s body. Companies such as Zimmer Biomet offer natural bone grafts (xenografts).

The bone graft substitutes segment is anticipated to witness lucrative growth in the field of spinal biologics owing to high adoption by surgeons and an increasing number of spinal fusion procedures. Also, the availability of advanced products in a variety of shapes and sizes providing high osteoconductive and osteoinductive properties is supporting its demand. Furthermore, a paradigm shift toward minimally invasive procedures is augmenting market growth globally.

End-use Insights

Based on end-use, the global spine biologics market has been segmented into hospitals, ambulatory surgical centers (ASCs), and others. The hospital segment accounted for the largest revenue share in 2018 and this trend is anticipated to continue throughout the forecast period. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities. However, in recent years, high hospitalization costs have translated into dipping patient admissions in hospitals, with the number of outpatient visits witnessing a surge. This is likely to threaten the adoption of spine biologics in hospital settings over the coming years.

Global spine biologics Market

The Ambulatory Surgery Center (ASC) segment is anticipated to witness lucrative growth in the market for spine biologics. Increasing demand for minimally invasive surgeries, technological developments in surgical devices and equipment, and surgeons’ control over the choice of such equipment are some of the factors projected to propel segment growth. Rising healthcare costs are a major concern plaguing the industry and with it comes the fact that not many patients can afford the treatment they need, including surgical procedures. This has compelled healthcare providers to come up with new ways to make such services more affordable while also focusing on quality. ASCs have proven to be an effective solution in this scenario.

Regional Insights

North America holds the largest share in the global market for spine biologics, followed by Europe. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as spinal stenosis, disc-related issues, and spondylolisthesis. According to the National Spinal Cord Injury Statistical Center, in 2017, approximately 285,000 people in the U.S. were reported to have been suffering from various spinal cord injuries.

The Asia Pacific market is anticipated to show significant growth due to the presence of a large patient pool and growing awareness among surgeons and patients pertinent to the benefits of biologics. Improvements in infrastructure and healthcare facilities in the region, rising healthcare expenditure, and the high prevalence of spine injuries, particularly due to road accidents, are some of the factors driving the regional market. Sedentary life and changing lifestyle patterns have resulted in an increasing prevalence of obesity, which is also likely to fuel the market over the coming years.

Spine Biologics Market Share Insights

The market is highly fragmented due to the presence of many leading players operating globally and occupying a significant share. The market is characterized by high competition based on price, product differentiation, and low cost of technology. It is also marked by an increased focus on the development of innovative products and a successful track record of mergers and acquisitions. Major manufacturers, raw material suppliers, and machinery manufacturers have been working in tandem to research, develop, and innovate new products within the field of spine biologics.

Some of the prominent players that fuel market growth are Stryker; Orthofix Holdings, Inc.; NuVasive, Inc.; K2M Inc.; DePuy Synthes; Wright Medical Group N.V.; Exactech, Inc.; Zimmer Biomet; Arthrex, Inc.; Medtronic Inc.; Organogenesis; and Lattice Biologics Ltd. In August 2018, Aziyo Biologics and RTI surgical Holdings, Inc., a global surgical implant company, signed an agreement wherein Aziyo provided its product ViBone (a bone repair product designed to perform autografts) to RTI surgical to be used in a variety of orthopedic procedures. This agreement was focused on exclusive distribution in the U.S. Such collaborations by major players will lend the market a significant boost.

Report Scope



The base year for estimation


Actual estimates/Historical data

2014 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million and CAGR from 2019 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., France, Italy, Spain, Russia, Japan, China, India, South Korea, Australia, Singapore, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analysts working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For this study, Grand View Research has segmented the global spine biologics market report based on product, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2014 - 2026)

    • Spinal Allografts

      • Machined Bones Allograft

      • Demineralized Bone Matrix

    • Bone Graft Substitutes

      • Bone Morphogenetic Proteins

      • Synthetic Bone Grafts

    • Cell-based Matrix

  • End-use Outlook (Revenue, USD Million, 2014 - 2026)

    • Hospitals

    • Ambulatory Surgical Centers

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2026)

    • North America

      • The U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Singapore

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon